Enanta Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ENTA Nasdaq 2834 www.enanta.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Jan 8th, 2025 12:00 pm
Sector Update: Health Care Stocks Mixed Tuesday Afternoon - Dec 24th, 2024 5:47 pm
Top Midday Decliners - Dec 24th, 2024 5:38 pm
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit - Dec 24th, 2024 12:00 pm
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? - Dec 23rd, 2024 2:43 pm
Enanta’s zelicapavir shows promise in paediatric respiratory syncytial virus trial - Dec 10th, 2024 5:34 pm
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) - Dec 9th, 2024 11:30 am
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) - Dec 6th, 2024 10:00 pm
Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility - Nov 29th, 2024 6:00 am
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates - Nov 25th, 2024 10:10 pm
Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot - Nov 25th, 2024 9:17 pm
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024 - Nov 25th, 2024 9:01 pm
The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable - Oct 27th, 2024 12:37 pm
Enanta Pharmaceuticals (ENTA): Promising Clinical Stage Biotech with Robust Pipeline - Oct 19th, 2024 3:13 pm
Millennium Management LLC's Strategic Acquisition of Enanta Pharmaceuticals Shares - Oct 17th, 2024 11:02 pm
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains? - Oct 2nd, 2024 11:53 am
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers - Sep 27th, 2024 10:45 am
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV) - Sep 26th, 2024 10:00 am
Enanta Pharmaceuticals to Participate in Investor Conferences in September - Sep 3rd, 2024 11:00 am
Enanta Pharmaceuticals, Inc. (ENTA): Caligan Partners’ Top Holding Right Now? - Aug 9th, 2024 11:27 am